60 results about "Epidermoid carcinoma" patented technology

The present invention provides methods of treating cancer cells comprising administering to a patient in need thereof a therapeutically effective amount of a non-specific antibody conjugated to a cytotoxin, wherein the cancer cells do not express an antigen to which the non-specific antibody binds. In one embodiment, the non-specific antibody is an anti-CD33 antibody (e.g., hp67.6), an anti-CD22 antibody (e.g., g5 / 44), or an anti-CD20 antibody (e.g., rituximab). In another embodiment, the non-specific antibody does not bind a human antigen. The cancer cells treated can be, e.g., gastric, colon, non-small cell lung (NSCLC), breast, epidermoid, or prostate carcinoma cells. In one embodiment, the cytotoxin is calicheamicin. Calicheamicin can be conjugated to the non-specific antibody using a 4-(4′-acetylphenoxy)butanoic acid (AcBut) or (3-Acetylphenyl)acetic acid (AcPAc) linker. In another embodiment, the antibody to the non-specific antigen conjugated to a cytotoxin is administered in combination with a bioactive agent, e.g., an anti-cancer agent.

The invention relates to secalonic acid H derived from penicillium oxalicum and application of the secalonic acid H for preparing a medicine for preventing human oral epidermoid carcinoma. The compound has a function of inhibiting human oral epidermoid carcinoma cell proliferation. The structural formula of the secalonic acid I is as shown in the specification. Through fermentation culture of Penicillium oxalicum IBPT-6, a fermented substance is prepared, and the compound is separated and purified from the fermented substance. Tests show that the compound has relatively high anti-tumor activity upon human oral epidermoid carcinoma cells KB. The compound can be used for preventing human oral epidermoid carcinoma cell proliferation inhibition medicines or anti-tumor medicines for studying human oral epidermoid carcinoma.

The invention relates to treatment of cancer. More specifically the invention relates to methods of treating cancer selected from the group consisting of squamous cell cancer, lung cancer including small-cell lung cancer, non-small cell lung cancer, adenocarcinoma of the lung, and squamous carcinoma of the lung, cancer of the peritoneum, hepatocellular cancer, gastric or stomach cancer including gastrointestinal cancer, pancreatic cancer, glioblastoma, cervical cancer, ovarian cancer, liver cancer, bladder cancer, hepatoma, breast cancer, colon cancer, colorectal cancer, endometrial or uterine carcinoma, salivary gland carcinoma, kidney or renal cancer, liver cancer, prostate cancer, vulval cancer, thyroid cancer, hepatic carcinoma and various types of head and neck cancer, as well as B-cell lymphoma including low grade / follicular non-Hodgkin's lymphoma (NHL); small lymphocytic (SL) NHL; intermediate grade / follicular NHL; intermediate grade diffuse NHL; high grade immunoblastic NHL; high grade lymphoblastic NHL; high grade small non-cleaved cell NHL; bulky disease NHL; mantle cell lymphoma; AIDS-related lymphoma; and Waldenstrom's Macroglobulinemia; chronic lymphocytic leukemia (CLL); acute lymphoblastic leukemia (ALL); Hairy cell leukemia; chronic myeloblastic leukemia; and post-transplant lymphoproliferative disorder (PTLD), as well as abnormal vascular proliferation associated with phakomatoses, edema such as that associated with brain tumors, Meigs' syndrome, melanoma, mesothelioma, multiple myeloma, fibrosarcoma, osteosarcoma and epidermoid carcinoma, by administering antibodies directed to α2β1 integrin.

The invention discloses a bis-beta-carboline alkali compound, and a preparation method, a pharmaceutical composition and application thereof. Specifically, the bis-beta-carboline alkali compound and a pharmaceutically acceptable salt thereof are shown in the general formula I. The bis-beta-carboline alkali compound is prepared by condensation of beta-carboline intermediates and dihaloalkane hydrocarbons. The invention further discloses a pharmaceutical composition and application of the bis-beta-carboline alkali compound in preparing anti-tumor drugs. The pharmaceutical composition comprises an effective dose of bis-beta-carboline alkali compound shown in the formula I and a pharmaceutically acceptable carrier, and the tumor comprises melanoma, gastric cancer, lung cancer, breast cancer, kidney cancer, liver cancer, oral epidermoid carcinoma, cervical cancer, ovarian cancer, pancreatic cancer, prostate cancer and colon cancer.

Folate modified cholesterol-bearing pullulan (FA-CHP) was synthesized by the reaction of folic acid γ-2-aminoethylamide and 4-nitorophenyl chloroformate-activated cholesterol-bearing pullulan, wherein folate and pullulan are connected through a NH—CH2—CH2—NH group. Approximately 0.5-1 folates are connected per about 100 glycoside units of pullulan. Then, several combinations of FA-CHP, cholesterol-bearing pullulan (CHP) and doxorubicin (DOX) mixture were tested for cancer selective cytotoxicity. A mixture of FA-CHP, CHP and DOX of 1:4:0.02 (weight ratio) gave sharp and selective damage to cells of a human epidermoid cancer KB known as expressing a high level of folate receptor. The same mixture inhibited the growth of HuH7 cells, which is a human hepatocellular carcinoma and is unknown as a folate receptor.

The invention discloses a 22-abeo-stigmasterol benzimidazole compound as well as a preparation method and application thereof. The structural formula of the 22-abeo-stigmasterol benzimidazole compound is shown in the specification; experiments for in-vitro inhibition of growth and proliferation activities of cancer cells show that the 22-abeo-stigmasterol benzimidazole compound prepared by the preparation method has remarkable inhibition effect to multiple tumor cell strains such as human papillary thyroid cancer cells, human oral epidermoid carcinoma cells, cancer cell strains of cervical cancer and the like. Meanwhile, the 22-abeo-stigmasterol benzimidazole compound has no cytotoxicity to human kidney epithelial cells (HEK293T) and can be applied to the preparation of drugs for treating cancers.

The invention discloses application of indeno triazine compounds as a substrate of quinone oxidoreductase depending on NAD (P) H. The indeno triazine compounds are catalyzed through the quinone oxidoreductase depending on the NAD (P) H to generate an oxidation reduction cycle reaction, a large number of reactive oxide free radicals are generated, strong oxidative stress is induced, and the obvious lethal effect on lung cancer, liver cancer, cervical cancer, pancreatic cancer, breast cancer, prostate cancer, nasopharynx cancer, kidney clear cell carcinoma, oral epidermoid carcinoma, chronic myelogenous leukemia, intestinal cancer, brain cancer, gastric cancer, esophagus cancer and other cancer cells expressed by the quinone oxidoreductase depending on the NAD (P) H is achieved. The indeno triazine compounds used as the substrate of the quinone oxidoreductase depending on the NAD (P) H can also be used as sensitizers for treating the cancer with radiotherapy, and have the obvious anticancer synergistic effect. In addition, the indeno triazine compounds used as the substrate of the quinone oxidoreductase depending on the NAD (P) H have antibacterial and antifungal activity.

The invention relates to the nucleic acid and polypeptide sequences of three novel human Ron-related gene variants (Ron-V1, Ron-V2, and Ron-V3). The invention also provides a process for producing the polypeptides of the variants, as well as uses for the nucleic acid, polypeptide and antibodies to same in diagnosing human breast carcinoma, breast adenocarcinoma, cervix epidermoid carcinoma, cervix epitheloid carcinoma, colon adenocarcinoma, urinary bladder carcinoma, prostate carcinoma, esophagus epidermoid carcinoma and esophagus carcinoma.

The present invention relates to a periplaneta americana extract effective part with cytotoxic activity, a preparation method and a medical purpose thereof. The periplaneta americana extract effective part of the present invention is refined from fresh or dry blattidae periplaneta americana body which is extracted by alcohol water, processed for macroporous resin column chromatography and is eluted by alcohol solvent. The periplaneta americana extract effective part obtained by the present invention has obvious cytotoxicity and internal anticancer efficacy towards oral epidermoid carcinoma (KB) cell, poorly differentiated gastric abenocarcinoma tumour (BGC-823) cell, human chronic myelogonium leukaemia cancer (K562) cell and human myelogonium leukaemia cancer cell (HL-60) and can be used for preparing for a drug and a health care product for remedying the tumours.

The invention discloses the application of nobiletin, in particular the application in the preparation of health products or medicines for preventing and / or treating oral cancer. The antiproliferative effects of nobiletin, naringenin and nobiletin on the human oral epidermoid cancer cell through the monomeric compounds nobiletin, naringenin and nobiletin in the citrus fruits of Rutaceae showed that nobietin, naringenin and nobiletin had the effect on human oral epidermoid cancer cells. The proliferation of cancer cells is obviously inhibited, and nobiletin has the most obvious effect of inhibiting the proliferation of oral cancer cells. It can be used to prepare health care products and medicines that can prevent and treat oral cancer, and is suitable for large-scale promotion.

Disclosed a saucernetin structurally simplified substance and the preparation method and pharmaceutical composition and use thereof. In particular, it relates to a compound of general formula (I) shown as formula (I) or an isomer thereof and a salt thereof, and the preparation method for such compounds. A novel pharmaceutical composition contains an effective amount of compound of formula I and a pharmacodynamically acceptable vector. The present invention also discloses the use of such compounds in preparing drugs for preventing and / or treating tumours. The tumours include neural glioblastoma, melanoma, gastric cancer, lung cancer, breast cancer, kidney cancer, liver cancer, oral epidermoid carcinoma, cervical cancer, ovarian cancer, pancreatic cancer, prostate cancer, and colon cancer and rectal adenocarcinoma.

The invention discloses an application of Sarcaboside B in preparation of medicines for treating lung cancer. The Sarcaboside B has good anti-lung cancer activity and can be used for the preparation of anti-lung cancer medicines, belonging to the technical field of new applications of medicines. The Sarcaboside B can be used for obviously inhibiting non-small cell lung cancer cells A549 cultured in vitro, giant cell lung cancer cells NCI-H460, lung squamous carcinoma cells HTB-8 and human lung epidermoid carcinoma cells QG-5 and has a little inhibiting effect on human normal hepatic cells LO2 and peripheral blood mononuclear cells and obvious selectivity. The application of the Sarcaboside B in preparation of the medicines for treating lung cancer is disclosed by the invention for the first time. As the skeleton type of the Sarcaboside B belongs to a brand-new skeleton type, the Sarcaboside B has unexpected strong inhibitory activity on lung cancer cells.

The invention discloses application of a thiourea molecule in preparation of antitumor drugs. The structural formula of the thiourea molecule is selected from formula I to formula IV, wherein R1, R2 and R3 are independently selected from hydrogen, alkyl with a carbon number of 1-10, aryl or a heteroatom group containing N, O and S. The invention provides new application of the thiourea molecule, specifically in preparation of anticancer drugs. The thiourea molecule is adopted as the anti-cancer drug, or is used as the active ingredient for preparation of pharmaceutical preparations, the antitumor drugs show very low cytotoxicity to human lung adenocarcinoma cells (A549), human breast cancer cells (BCap-37), human oral epidermoid carcinoma cells (KB), human lung fibroblast (HFL1) and human bronchial epithelial cells (BEAS-2B), but has very good antitumor effect at the animal level. (formula I, formula II, formula III, and formula IV).

The invention discloses an application of an EGFR inhibitor in the preparation of a drug for the treatment of MUC1-positive tumors, and relates to the application of an inhibitor targeting the MUC1-EGFR-ABCB1 signaling pathway in combination with an ABCB1 substrate chemotherapeutic drug in the preparation of a drug for the treatment of MUC1-positive tumors. The present invention discloses the molecular mechanism by which chemotherapeutic drugs induce MUC1 expression and activate the MUC1-EGFR-ABCB1 signaling pathway in cervical cancer and lung mucoepidermoid cancer, and finally cause cells to pump the drugs out of the membrane to produce drug resistance. At the same time, targeted inhibition of EGFR can effectively inhibit the proliferation of cervical cancer and lung mucoepidermoid cancer cells, control the growth of transplanted tumors, and effectively prevent the recurrence of transplanted tumors. It is suggested that the combination of inhibitors targeting MUC1-EGFR-ABCB1 signaling pathway and ABCB1 substrate chemotherapeutic drugs has broad prospects in the preparation of MUC1-positive tumor drugs.